RCaz/eu-funding-proposals-sft huggingface dataset:
system: You are an expert grant writer specializing in European Union research funding proposals. You write compelling, well-structured proposal sections that demonstrate excellence, impact, and implementation quality, using precise EU terminology and following best practices for Horizon Europe, Horizon 2020, and earlier framework programmes.

user: Describe the specific objectives and expected outcomes for 'Role of Listerin ubiquitin ligase in MHC-I antigen presentation' in the context of a Horizon 2020 call.

assistant: **Objectives**

Mammalian cells present a fingerprint of their proteome through the display of endogenous peptides on MHC-I complexes. This allows for CD8+ T cells to recognize and kill cells infected with viruses or other intracellular parasites, or cells accumulating aberrant proteins resulting from malignant transformation. The MHC-I peptides originate from protein degradation by the ubiquitin proteasome system, which is responsible for controlled protein turnover. This would mean that viral proteins, which are typically very stable, would escape monitoring. Nevertheless, cells are able to mount an MHC-I immune response minutes after viral infection. Most MHC-I presented peptides are therefore thought to originate from newly synthesized, defective ribosomal products (DRiPs), rather than proteins at the end of their lifespan. Although there is a growing body of evidence showing that antigen presentation is better correlated with protein synthesis rather than protein stability, characterization of the underlying cellular pathway is lacking. Recently, the E3 ubiquitin ligase Listerin has been shown to mark nascent polypeptides resulting from defective mRNAs for degradation. Here we test the hypothesis that this pathway contributes to the production of peptides for MHC-I loading. Our major aim is therefore to investigate the involvement of Listerin in antigen presentation, using 3 different approaches: I) proof-of-principle experiments analyzing the rate of MHC-I presentation of a model protein, comparing the efficiency of its presentation when expressed from an intact or defective mRNA, and when expressed in WT or Listerin knock-out cells; II) global characterization of the MHC-I peptidome of WT and Listerin knock-out cells using mass spectrometry; III) quantitative analysis of the fra
system: You are an expert grant writer specializing in European Union research funding proposals. You write compelling, well-structured proposal sections that demonstrate excellence, impact, and implementation quality, using precise EU terminology and following best practices for Horizon Europe, Horizon 2020, and earlier framework programmes.

user: Describe the novelty, innovation potential and advance beyond the state of the art for 'Pico: no more passwords' (PICO).

assistant: **Innovation**

Passwords, passphrases and PINs have become a usability disaster. Even though they are convenient for implementers, they have been over-exploited, and are now increasingly unmanageable for end users, as well as insecure. The demands placed on users (passwords that are unguessable, all different, regularly changed and never written down) are no longer reasonable now that each person has to manage dozens of passwords. This project will develop and evaluate an alternative design based on a hardware token called Pico that relieves the user from having to remember passwords and PINs. Besides relieving the user from memorization efforts, the Pico solution scales to thousands of credentials, provides ``continuous authentication'' and is resistant to brute force guessing, dictionary attacks, phishing and keylogging. To promote adoption and interoperability, the Pico design has not been patented. The Principal Investigator has been invited to speak about Pico in three continents (including at USENIX Security 2011) since releasing the first draft of his design paper.
system: You are an expert grant writer specializing in European Union research funding proposals. You write compelling, well-structured proposal sections that demonstrate excellence, impact, and implementation quality, using precise EU terminology and following best practices for Horizon Europe, Horizon 2020, and earlier framework programmes.

user: Compose a compelling abstract for 'Manufacturing and Development for Rapid Access Ebola Vaccine (EBOMAN) – Sofia ref.: 115850' demonstrating excellence, impact and implementation quality for a Horizon 2020 call.

assistant: **Abstract**

This topic response (Topic 2: Manufacturing Capability) forms part of an integrated proposal to address the urgent unmet needs of accelerating the development of an Ebola vaccine. To help facilitate this main goal additional activities will be performed; the generation of sufficient vaccine and the capacity increase for generating more vaccine by means of process scale up and improvements.The main objectives of this proposal are to manufacture sufficient supplies (and overages) for the clinical studies described in topic 1 and to prepare for a rapid access to large quantities of Ad26.ZEBOV (prime) and MVA-BN®-Filo (boost) vaccine in case of further escalation of the Ebola outbreak (The clinical development may change requiring an alternative vaccine combination; vaccination strategy. Any changes will be subsequently reflected in the manufacturing of clinical supplies). In conjunction with topic 3 (Transport and Rapid Access Ebola Vaccine) we should be able to respond quickly to future emergency needs of the vaccine.The program therefore covers immediate manufacturing of clinical material and creation of additional capacity (by scale up, process improvements) and product understanding (BSL classification downgrading, process and product characterisation) to cope with increased need for the vaccine. The program includes:Manufacturing, release and supply of Ad26.ZEBOV and MVA-BN®-Filo vaccine candidate for clinical studies (outcome: released clinical material)Process Development activities required to ensure scale up of Ad26.ZEBOV manufacturing to 50L and fully define the 300L scale MVA BN®-Filo production.Execute process development activities to ensure scale up of Ad26.ZEBOV and MVA-BN®-Filo to support potential manufacturing of up to 4M dosesProcess Development and furt
system: You are an expert grant writer specializing in European Union research funding proposals. You write compelling, well-structured proposal sections that demonstrate excellence, impact, and implementation quality, using precise EU terminology and following best practices for Horizon Europe, Horizon 2020, and earlier framework programmes.

user: Explain how 'European Consortium for the Study of a Topical Treatment of  iCRVO to prevent Neovascular Glaucoma' goes beyond current state-of-the-art under Seventh Framework.

assistant: **Innovation**

Neovascular glaucoma (NVG) is a very aggressive and rare type of glaucoma: yet, it contributes disproportionately to blindness from all eye diseases. NVG is also the second most common cause for the removal of the eye-ball across all eye diseases, usually because of intractable pain. The major cause of NVG is Ischaemic Central Retinal Vein Occlusion (CRVO) leading to neovascularisation, obstruction of aqueous humour outflow and increased intraocular pressure. Today’s therapeutic approaches are insufficient: they include destruction of the retina by coagulation, or off-label anti-VEGF injection into the eye. It is proposed to develop a better treatment by assessing the topical administration of Aganirsen: it is an antisense oligonucleotide able to interrupt the production of Vascular Endothelial Growth Factor, which plays a major role in the pathogenesis of NVG. Aganirsen is developed by GENE SIGNAL, a SME with expertise in topical ophthalmic treatments for orphan diseases, and manufactured by UNITHER. Under the coordination of the Mainz University Medical Center, a Phase II/III randomised, double-masked, 3-group, placebo-controlled trial (STRONG) is therefore presented to assess Aganirsen’s efficacy in reducing the rate of anterior and posterior segment neovascularisation and NVG development after CRVO. Involving 333 subjects within more than 35 clinical sites, the study is operationalized via a disease specific network (EVICR.net) and a contract research organization managed by GENE SIGNAL. The study aims at assessing a new therapeutic approach for iCRVO to prevent NVG for which conditional authorization will be sought at the end of the project. STRONG also delivers new insights into the natural course of the disease and its risk factors, analysing one of the largest p
system: You are an expert grant writer specializing in European Union research funding proposals. You write compelling, well-structured proposal sections that demonstrate excellence, impact, and implementation quality, using precise EU terminology and following best practices for Horizon Europe, Horizon 2020, and earlier framework programmes.

user: Draft the 'Objectives and Scope' section of a Seventh Framework proposal for the project 'microRNA-155 expression control and function in innate immune inflammatory response'.

assistant: **Objectives**

MicroRNAs (miRNAs) are small non-coding RNAs which play critical roles in key biological processes, including immune response. miRNAs derive from transcripts (pri-miRNAs) which are processed by Drosha into intermediate hairpin precursors (pre-miRNAs). Pre-miRNAs are then processed by Dicer into mature forms of about 22 nucleotides. Mature miRNAs are loaded in the RNA-induced silencing complex (RISC) to mediate degradation and/or translation inhibition of specific target mRNAs. Many reports documented discrepancies in the levels of precursors and mature miRNAs indicating a wide potential for post-transcriptional control of miRNA expression. We recently discovered that the terminal loop structure of miRNA precursors plays a pivotal role as dock for co-activators of miRNA processing (e.g. KSRP) or co-repressors (e.g. Lin28), acting in a coordinated way to control miRNA biogenesis. Among the miRNAs post-transcriptionally regulated by KSRP we identified miR-155. miR-155 regulates both adaptive and innate immune responses. In macrophages, miR-155 maturation is induced upon lipopolysaccharide (LPS) stimulus. I hypothesize that a repressor complex is bound to pri-miR-155 in untreated macrophages to block the recruitment of KSRP and thus the maturation. LPS stimulus induces the dismissal of the repressor and the recruitment of the activator complex to pri-miR-155. Aims of my future work will be to identify in macrophages: i) the components of the regulatory complex(es) for miR-155 biogenesis; ii) the dynamics and the post-translational modifications that modulate the exchange between regulatory complexes; iii) novel miR-155 direct target mRNAs. This study will delineate the regulatory network that controls miR-155 maturation and function in macrophages allowing the design and th
system: You are an expert grant writer specializing in European Union research funding proposals. You write compelling, well-structured proposal sections that demonstrate excellence, impact, and implementation quality, using precise EU terminology and following best practices for Horizon Europe, Horizon 2020, and earlier framework programmes.

user: Draft an impact statement for 'RESURRECT YOUR ZOMBIAPP. OR ARE YOU JUST GOING TO LET IT DIE?', explaining its relevance to EU policy priorities under Horizon 2020.

assistant: **Impact**

The emerging game app mobile market has shown great economy potential. However, revenues are highly concentrated. At the top end of the revenue scale there are just 1.6% of developers, while 57% of app games are below the ‘app poverty line’ due to two main problems:1) Developers find difficulties for getting their new apps noticed. App developers believe that marketing is necessary for success, but small developers such as SMEs, entrepreneurs and independent developers cannot afford or take advantage of current marketing tools. 2) Obtaining user downloads is no longer enough in order to build a great business with mobile apps. The most successful game apps are free-to-play, monetising a tiny fraction of their audience via consumable in-app purchases. A recent study shows that, in average, developers invest €139 in marketing for each €100 they earn. Thus, user attraction can be easily but costly boosted by current approaches but user retention and optimizing revenues per user to support apps with freemium strategies is still an on-going issue. BIKO intends to offer a disruptive game apps marketing tool, the ZombiApp service, with a twofold innovative approach: 1) Automated assessment of users interaction for marketing recommendations.2) User profiling/segmentation for cross-promotion focused on user engagement, IAPs monetization strategy and user expenditure behaviour. The service will redirect users within the network to indicated games in timely moments taking into account its monetization potential in the current app (the likelihood of these user still spending money on it) and the estimated exhaustion points of the app (when users tend to uninstall the game). Moreover, BIKO proposes a disruptive business model based on a shared revenue approach easing the access to a
system: You are an expert grant writer specializing in European Union research funding proposals. You write compelling, well-structured proposal sections that demonstrate excellence, impact, and implementation quality, using precise EU terminology and following best practices for Horizon Europe, Horizon 2020, and earlier framework programmes.

user: Compose the 'State of the Art and Innovation' section for a Horizon Europe proposal on 'Dry Powder Formulation of RNA Nanoparticles for Inhalation and Improved Storage and Transport Conditions'.

assistant: **Innovation**

RNhale aims to establish technical and commercial proof-of-concept for our existing and protected protocols to be transformed into a platform technology with the long-term goal of licensing agreements with large pharmaceutical companies which are equipped for continuous manufacturing of large scales of dry powder RNA formulations.  RNhale will assess the commercial positioning of a platform technology for spray-drying RNA nanoparticles (NPs). While RNA medicines have revolutionized how we can address a pandemic, RNA therapeutics have not yet broadly changed patient outcomes but are specifically used for very limited indications due to two main reasons: (i) the high immunogenicity and poor stability of RNA; and (ii) the accumulation of nano-encapsulated RNA in the liver and resulting poor targetability of other organs with RNA-loaded NPs. These shortcomings have been addressed in my current ERC project Novel Asthma Therapy by spray-drying polymer-based RNA NPs.  RNhale will refine existing protocols for spray-drying RNA NPs made with diverse RNA NPs to overcome current challenges by: 1) improving storage and transport conditions of spray-dried RNA medicines in general; and 2) gaining access to delivery beyond the liver via inhalation delivery to the lung.
system: You are an expert grant writer specializing in European Union research funding proposals. You write compelling, well-structured proposal sections that demonstrate excellence, impact, and implementation quality, using precise EU terminology and following best practices for Horizon Europe, Horizon 2020, and earlier framework programmes.

user: Write the concept and methodology overview for 'Nice but incompetent? The eldery stereotype in Europe' under Seventh Framework.

assistant: **Concept**

Europe’s constantly ageing population posits a number of challenges for the European Community. One of the main issues lies in shedding age discrimination that prevents the social inclusion of older people in society. A first step in doing so is to identify negative stereotypes and to uncover the mechanisms that lead to them. Past research has focused solely on psychological factors neglecting the societal context. Hence, the proposed research aims to fill this important gap by investigating the joint impact of societal and psychological variables on shaping age stereotypes and ageism. For this purpose, an explanatory model is developed and tested in a series of four cross-cultural studies.In the first phase of the project (Study 1 and 2) secondary data from the Ageism module in the European Social Survey will be analyzed. Data are available from more than 50,000 individuals coming from 28 countries in Europe. An explanatory model will be tested with the use of multilevel structural equation modeling that allows examining psychological and societal predictors simultaneously. Study 1 will focus on younger and middle-aged people’s attitudes towards the elderly by examining outcome variables such as prejudice and intergenerational contact. Study 2 will concentrate on the elderly and investigate outcome variables such as experiences of ageism and subjective well-being. In the second phase of the project, a systematic cross-cultural survey will be constructed to further investigate the impact of different societal stereotypes on real-life issues that were not assessed in the ESS. In Study 3, 400 older people from four countries will be surveyed and among others their self-esteem and willingness to engage in voluntary work will be assessed. Study 4 is a quasi-experimental fie
system: You are an expert grant writer specializing in European Union research funding proposals. You write compelling, well-structured proposal sections that demonstrate excellence, impact, and implementation quality, using precise EU terminology and following best practices for Horizon Europe, Horizon 2020, and earlier framework programmes.

user: Compose a compelling abstract for 'Investigation of biopsychoSocial Influences on Gender during diverse Hormonal Transitions' demonstrating excellence, impact and implementation quality for a Horizon Europe call.

assistant: **Abstract**

Gender-InSIGHT aims to equip a new generation of interdisciplinary researchers with tools from disciplines including psychology, history, ethics, endocrinology, neuroscience, and public health. Through co-creation and mixed-methods research, doctoral candidates will increase understanding of the influence of biopsychosocial factors on gender during diverse hormonal transitions, including variations in puberty and menopause. Specific attention will be paid to groups historically marginalized in such research, for example trans and gender diverse people and those with variations of sex characteristics. Historical, clinical, and societal lenses will focus attention on, respectively, documenting the history and ethical implications of the shifts in meaning given to biopsychosocial factors in the framing of hormones and gender over time; providing clinical guidance informed by a biopsychosocial understanding of gender to assist patients and healthcare providers with decision-making regarding diverse hormonal transitions; and uncovering societal pressures and polarization regarding the biopsychosocial nature of gender and how these are communicated across cultures and through different channels. The training programme is designed to broaden and deepen interdisciplinary knowledge and to advance research skills, methodological expertise, and transferrable skills. Novel data, methods, and tools will be disseminated through a wide range of channels to ensure all stakeholders are reached. Collaboration with partners from non-academic domains promotes effective knowledge exchange and stimulates patient-provider engagement, collaboration in decision-making, and building infrastructure around research results of Gender-InSIGHT. This will have a lasting impact on culture and media, he
system: You are an expert grant writer specializing in European Union research funding proposals. You write compelling, well-structured proposal sections that demonstrate excellence, impact, and implementation quality, using precise EU terminology and following best practices for Horizon Europe, Horizon 2020, and earlier framework programmes.

user: Explain the overall concept, methodology and approach for the project 'Deciphering Irish Alcohol and Substance use: Post-war Representations and Accounts' (DIASPORA).

assistant: **Concept**

DIASPORA will focus on the Irish in post-war London and New York to provide a nuanced and penetrative investigation of the intersections between alcohol, drug use, mental health, migration and ethnicity. Crucially, it will interrogate the cultural and societal implications of the ubiquitous “drunken Irish” label, the disproportionate rates of alcoholism reported among Irish migrants/diaspora, and the perceived day-to-day roles of recreational drugs, drink and drinking spaces – both positive and negative – in the lived experiences of this cohort. The project will trace the interplay between expert, state, religious and cultural representations, before contrasting findings with first-hand accounts by Irish migrants/diaspora. By casting alcohol and drugs as prisms through which to view experiences and portrayals of the Irish abroad, the project will expose fault lines in existing historical studies of (i) Irish migration; (ii) migration, health and ethnicity; and (iii) alcohol and drugs, which have eschewed any meaningful examination of this topic. By drawing together these ordinarily distinct strands of historiography, and placing an ethnic stereotype at the centre of its investigation, it will redefine scholarly debates about other ethnic groups, as well as broader discourses on the physical and mental implications of migration and discrimination. DIASPORA’s overarching aim is to use the longevity of Irish migration to London and New York to enlighten the evolving ethnic and racial experience in Britain and the US. The project will offer a blueprint for future comparative analyses of health, ethnicity and race in historical perspective. To do so, it will blend traditional historical methodologies, including robust archival research on government files and Irish community